Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis - PubMed
8 hours ago
- #CD38 monoclonal antibody
- #multiple myeloma
- #meta-analysis
- CD38 monoclonal antibodies (daratumumab, isatuximab) show efficacy in relapsed/refractory multiple myeloma (MM).
- Systematic review and meta-analysis of 8 RCTs (2,821 patients) confirms improved overall response rate (ORR: RR 1.59) and progression-free survival (PFS: HR 0.50).
- Benefits consistent across subgroups (renal function, age, prior therapy lines).
- Higher rates of non-hematologic adverse events (infections, diarrhea) with CD38-targeted therapies.
- Supports integration of CD38 antibodies into MM treatment algorithms with acceptable safety profile.